AstraZeneca Pharma India Limited

NSEI:ASTRAZEN 주식 보고서

시가총액: ₹172.9b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

AstraZeneca Pharma India 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Sanjeev Panchal

최고 경영자

₹21.1m

총 보상

CEO 급여 비율24.2%
CEO 임기1.5yrs
CEO 소유권n/a
경영진 평균 재임 기간less than a year
이사회 평균 재임 기간1.5yrs

최근 관리 업데이트

Recent updates

We Believe AstraZeneca Pharma India's (NSE:ASTRAZEN) Earnings Are A Poor Guide For Its Profitability

Jun 03
We Believe AstraZeneca Pharma India's (NSE:ASTRAZEN) Earnings Are A Poor Guide For Its Profitability

Why Investors Shouldn't Be Surprised By AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) P/S

May 22
Why Investors Shouldn't Be Surprised By AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) P/S

We Ran A Stock Scan For Earnings Growth And AstraZeneca Pharma India (NSE:ASTRAZEN) Passed With Ease

Apr 04
We Ran A Stock Scan For Earnings Growth And AstraZeneca Pharma India (NSE:ASTRAZEN) Passed With Ease

Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?

Nov 10
Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?

AstraZeneca Pharma India's (NSE:ASTRAZEN) Dividend Will Be Increased To ₹16.00

Jul 06
AstraZeneca Pharma India's (NSE:ASTRAZEN) Dividend Will Be Increased To ₹16.00

Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?

Jun 16
Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?

Increases to CEO Compensation Might Be Put On Hold For Now at AstraZeneca Pharma India Limited (NSE:ASTRAZEN)

Aug 02
Increases to CEO Compensation Might Be Put On Hold For Now at AstraZeneca Pharma India Limited (NSE:ASTRAZEN)

Here's Why I Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is An Interesting Stock

Feb 25
Here's Why I Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is An Interesting Stock

Could The AstraZeneca Pharma India Limited (NSE:ASTRAZEN) Ownership Structure Tell Us Something Useful?

Feb 04
Could The AstraZeneca Pharma India Limited (NSE:ASTRAZEN) Ownership Structure Tell Us Something Useful?

Declining Stock and Solid Fundamentals: Is The Market Wrong About AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?

Jan 18
Declining Stock and Solid Fundamentals: Is The Market Wrong About AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?

Announcing: AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Increased An Energizing 282% In The Last Five Years

Dec 31
Announcing: AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Increased An Energizing 282% In The Last Five Years

We're Not Counting On AstraZeneca Pharma India (NSE:ASTRAZEN) To Sustain Its Statutory Profitability

Dec 13
We're Not Counting On AstraZeneca Pharma India (NSE:ASTRAZEN) To Sustain Its Statutory Profitability

Here's Why We Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is Well Worth Watching

Nov 25
Here's Why We Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is Well Worth Watching

Here's What We Think About AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Pay

Nov 07
Here's What We Think About AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Pay

What Kind Of Investors Own Most Of AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?

Oct 20
What Kind Of Investors Own Most Of AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?

AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Sep 24
AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

If You Had Bought AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Three Years Ago, You Could Pocket A 298% Gain Today

Aug 28
If You Had Bought AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Three Years Ago, You Could Pocket A 298% Gain Today

What Did AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Take Home Last Year?

Aug 02
What Did AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Take Home Last Year?

Could The AstraZeneca Pharma India Limited (NSE:ASTRAZEN) Ownership Structure Tell Us Something Useful?

Jul 12
Could The AstraZeneca Pharma India Limited (NSE:ASTRAZEN) Ownership Structure Tell Us Something Useful?

CEO 보상 분석

Sanjeev Panchal 의 보수는 AstraZeneca Pharma India 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Mar 31 2024n/an/a

₹2b

Dec 31 2023n/an/a

₹1b

Sep 30 2023n/an/a

₹2b

Jun 30 2023n/an/a

₹1b

Mar 31 2023₹21m₹5m

₹993m

보상 대 시장: Sanjeev 의 총 보상 ($USD 253.41K ) Indian 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 438.56K ).

보상과 수익: Sanjeev 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.


CEO

Sanjeev Panchal (47 yo)

1.5yrs

테뉴어

₹21,149,014

보상

Dr. Sanjeev Kumar Panchal serves as Country President of AstraZeneca Pharma India Limited since January 01, 2023 and serves as its Managing Director since January 01, 2023. He serves as Director of AstraZe...


리더십 팀

이름위치테뉴어보상소유권
Sanjeev Panchal
MD, Country President & Director1.5yrs₹21.15m데이터 없음
Bhavana Agrawal
Whole-Time Director & CFOless than a year데이터 없음데이터 없음
Pratap Bhuvanagiri
Legal Counsel7.4yrs₹3.73m데이터 없음
Manasa R.
Company Secretary & Compliance Officer1.9yrs데이터 없음데이터 없음
Smita Saha
Vice President of Human Resourcesno data₹12.28m데이터 없음
Ayush Agarwal
Interim Business Unit Head of Oncology & Director of Commercial Excellenceless than a year데이터 없음데이터 없음
Praveen Akkinepally
Head of Oncology Business Unitless than a year데이터 없음데이터 없음
Vinay Sharma
Business Unit Head - Rare Disease unitno data데이터 없음데이터 없음
Vimlesh Maheshwari
Finance Controllerno data데이터 없음데이터 없음

1.0yrs

평균 재임 기간

경험이 풍부한 관리: ASTRAZEN 의 관리팀은 경험 (평균 재직 기간 1.2 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.


이사회 구성원

이름위치테뉴어보상소유권
Sanjeev Panchal
MD, Country President & Director1.5yrs₹21.15m데이터 없음
Bhavana Agrawal
Whole-Time Director & CFOless than a year데이터 없음데이터 없음
Revathy Ashok
Independent Non-Executive Director7.6yrs₹1.20m데이터 없음
Narayan Seshadri
Independent Chairman of the Board11.6yrs₹1.40m데이터 없음
Hooi Chuah
Additional Non-Executive Directorless than a year데이터 없음데이터 없음
Nirula Shilpa Divekar
Independent Non-Executive Director2.6yrs₹1.30m데이터 없음
Sylvia Lorena Ramon
Non-Executive Directorless than a year데이터 없음데이터 없음

1.5yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 이사회: ASTRAZEN 의 이사회경험(평균 재직 기간 1.4 년)으로 간주되지 않으므로 새 이사회가 필요합니다.